In Situ Comparison of the Remineralization Potential of Optimized Fluoride Dentifrice With Control Fluoride Dentifrice
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06010732 |
Recruitment Status :
Completed
First Posted : August 25, 2023
Last Update Posted : April 25, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Caries | Drug: 0 ppm F (placebo, negative control) Drug: 1100 ppm F as sodium fluoride (positive control) Drug: 1100 ppm F as sodium fluoride Test Product | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 52 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Masking Description: | double blind |
Primary Purpose: | Prevention |
Official Title: | Comparison of the Remineralization Potential of an Optimized Fluoride Dentifrice With a Control Fluoride Dentifrice Using an in Situ Caries Model |
Actual Study Start Date : | October 2, 2023 |
Actual Primary Completion Date : | February 8, 2024 |
Actual Study Completion Date : | February 22, 2024 |
Arm | Intervention/treatment |
---|---|
Treatment Period 1
0 ppm F (placebo, negative control,1100 ppm F as sodium fluoride (positive control), 1100 ppm F as sodium fluoride Test Product
|
Drug: 0 ppm F (placebo, negative control)
• Each subject will use this product during one of the three treatment periods in the crossover study design.
Other Name: Tom's of Maine Silly Strawberry Drug: 1100 ppm F as sodium fluoride (positive control) • Each subject will use this product during one of the three treatment periods in the crossover study design.
Other Name: Crest Cavity Protection Toothpaste Drug: 1100 ppm F as sodium fluoride Test Product • Each subject will use this product during one of the three treatment periods in the crossover study design.
Other Name: Pronamel Daily Protection |
Treatment Period 2
0 ppm F (placebo, negative control,1100 ppm F as sodium fluoride (positive control), 1100 ppm F as sodium fluoride Test Product
|
Drug: 0 ppm F (placebo, negative control)
• Each subject will use this product during one of the three treatment periods in the crossover study design.
Other Name: Tom's of Maine Silly Strawberry Drug: 1100 ppm F as sodium fluoride (positive control) • Each subject will use this product during one of the three treatment periods in the crossover study design.
Other Name: Crest Cavity Protection Toothpaste Drug: 1100 ppm F as sodium fluoride Test Product • Each subject will use this product during one of the three treatment periods in the crossover study design.
Other Name: Pronamel Daily Protection |
Treatment Period 3
0 ppm F (placebo, negative control,1100 ppm F as sodium fluoride (positive control), 1100 ppm F as sodium fluoride Test Product
|
Drug: 0 ppm F (placebo, negative control)
• Each subject will use this product during one of the three treatment periods in the crossover study design.
Other Name: Tom's of Maine Silly Strawberry Drug: 1100 ppm F as sodium fluoride (positive control) • Each subject will use this product during one of the three treatment periods in the crossover study design.
Other Name: Crest Cavity Protection Toothpaste Drug: 1100 ppm F as sodium fluoride Test Product • Each subject will use this product during one of the three treatment periods in the crossover study design.
Other Name: Pronamel Daily Protection |
- Percent Surface Microhardness Recovery (%SMH Recovery) [ Time Frame: Two weeks ]
The SMH test will be used to assess changes in the mineral status of partially demineralized enamel specimens.
%SMH Recovery = (D1-R)/(D1-B) ×100 B = indentation length (µm) of sound enamel specimen at baseline D1 = indentation length (µm) after in vitro demineralization R = indentation length (µm) after intra-oral exposure.
- Enamel Fluoride Uptake (µg F/cm2) [ Time Frame: Two weeks ]The microdrill enamel biopsy technique will be used to analyze the fluoride content of the partially demineralized enamel specimens. Each enamel specimen will be mounted perpendicular to the long axis of a drill bit attached to a specially designed microdrill and drilled to a depth of ~100 µm through the entire lesion (four cores per specimen). The diameter of the drill hole will be determined using a calibrated microscope interfaced with an image analysis system. The amount of fluoride-uptake by enamel will be calculated based on the amount of fluoride divided by the area of the enamel cores and expressed as µg F/cm2
- Percent Net Acid Resistance [ Time Frame: Two weeks ]% Net Acid Resistance = [(D1-D2) / (D1-B)] * 100 B= Indentation length (µm) of sound enamel at baseline D1= Indentation length (µm) after first in vitro demineralization D2= Indentation length (µm) after second in vitro demineralization
- Percentage Comparative Acid Resistance [ Time Frame: Two weeks ]% Comparative Acid Resistance = [(D2-R) / (D1-B)] * 100 B= Indentation length (µm) of sound enamel at baseline R= Indentation length (µm) of enamel after in situ remineralization D1= Indentation length (µm) after first in vitro demineralization D2= Indentation length (µm) after second in vitro demineralization
- Integrated Mineral Loss (∆Z) [ Time Frame: Two weeks ]∆Z= [(lesion depth x 87) - area under the curve*] calculated using Transverse Microradiography software program
- Lesion Depth (µm) [ Time Frame: Two weeks ]Lesion Depth - L (83% mineral i.e. 95% of the mineral content of sound enamel) determined using Transverse Microradiography software program
- Maximum mineral density at the surface-zone (SZmax) [ Time Frame: Two weeks ]SZmax will be determined using Transverse Microradiography software program
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- provide voluntary, written informed consent;
- be between 18 and 85 years old;
- understand and be willing, able and likely to comply with all study procedures and restrictions;
- be wearing a removable mandibular partial denture with sufficient room to accommodate two 4 mm round specimens in the buccal surface of two posterior denture teeth on the same side;
- be willing and capable of wearing their removable partial denture 24 hours a day for three (3), two-week treatment periods;
- be willing to allow study personnel to drill specimen sites in two denture teeth in the posterior section of one side of their lower partial denture, which may extend into the buccal flange area below the teeth;
- be in good medical and dental health with no active caries or periodontal disease; NOTE: subjects presenting at screening with caries may continue in the study if their carious lesions are restored prior to beginning treatment 1; and
- have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 mL/min; gum base stimulated whole saliva flow rate ≥ 0.8 mL/min).
Exclusion Criteria:
- currently be pregnant, intending to become pregnant during the study period or breast feeding;
- currently have any medical condition that could be expected to interfere with the subject's safety during the study period;
- currently be taking antibiotics or have taken antibiotics in the two weeks prior to the beginning treatment 1;
- known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients;
- have participated in another clinical study or receipt of an investigational drug within 30 days of beginning treatment 1; or
- be taking fluoride supplements, required to use a fluoride mouthrinse or have received a professional fluoride treatment in the two weeks preceding specimen placement.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06010732
United States, Indiana | |
Indiana University School of dentistry, Oral Health Research institute 415 Lansing Street | |
Indianapolis, Indiana, United States, 46202 |
Principal Investigator: | Domenick Zero, DDS, MS | Indiana University | |
Principal Investigator: | Anderson Hara, DDS, PhD | Indiana University | |
Principal Investigator: | Frank Lippert, PhD | Indiana University |
Responsible Party: | Domenick Zero, Principal Investigator, Indiana University |
ClinicalTrials.gov Identifier: | NCT06010732 |
Other Study ID Numbers: |
23-I-121 |
First Posted: | August 25, 2023 Key Record Dates |
Last Update Posted: | April 25, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Caries Remineralization Fluoride Dentifrice |
Listerine Fluorides Sodium Fluoride Cariostatic Agents |
Protective Agents Physiological Effects of Drugs Anti-Infective Agents, Local Anti-Infective Agents |